An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation

Study Purpose:

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

Study Status:

Not recruiting

Disease:

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Study Type:

Interventional

Type of Intervention:

Drug

Intervention Name:

BIIB067

Placebo:

No

Phase:

Phase 3

Study Chair(s)/Principal Investigator(s):

Medical Director, Biogen

Clinicaltrials.gov ID:

NCT03070119

Neals Affiliated?

No

Coordinating Center Contact Information

Study Sponsor:

Biogen

Estimated Enrollment:

138

Estimated Study Start Date:

03 / 08 / 2017

Estimated Study Completion Date:

06 / 13 / 2024

Posting Last Modified Date:

03 / 03 / 2023

Date Study Added to neals.org:

03 / 03 / 2017

Minimum Age:

18 Years

Maximum Age:

N/A

Can participants use Riluzole?

Yes

Key Inclusion Criteria:

- Must have diagnosis of superoxide dismutase 1-amyotrophic lateral sclerosis (SOD1-ALS), and must have completed the End of Study Visit for either Parts A, B, or C of Study 233AS101 (NCT02623699) (i.e., were not withdrawn).

- If taking riluzole, participant must be receiving a stable dose for ≥30 days prior to Day 1.

- If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1. Edaravone may not be administered on dosing days during this study.

- Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.

- For female participants of childbearing potential must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.

- Participants from Study 233AS101 Parts A and B must have a washout ≥16 weeks between the last dose of study treatment received in Study 233AS101 and the first dose of BIIB067 received in the current Study 233AS102.

Key Exclusion Criteria:

- History of allergies to a broad range of anesthetics.

- Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for bleeding during or after a Lumbar Puncture (LP) procedure. These risks could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).

- Presence of an implanted shunt for the drainage of CSF or an implanted central nervous system (CNS) catheter.

- Prior or current treatment with small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy.

- Treatment with another investigational drug, biological agent (excluding BIIB067), or device within 1 month or 5 half-lives of study agent, whichever is longer.

- Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period.

- Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine.

- Female participants who are pregnant or currently breastfeeding.

- Current enrollment in any other interventional study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Research Site

Phoenix, Arizona 85013
United States

Research Site

La Jolla, California 92093-0949
United States

Research Site

San Francisco, California 94118
United States

Research Site

Jacksonville, Florida 32224
United States

Research Site

Miami, Florida 33136
United States

Research Site

Orlando, Florida 32806
United States

Research Site

Atlanta, Georgia 30322
United States

Research Site

Chicago, Illinois 60611
United States

Research Site

Baltimore, Maryland 21287
United States

Research Site

Boston, Massachusetts 02114
United States

Research Site

Rochester, Minnesota 55905
United States

Research Site

Saint Louis, Missouri 63110
United States

Research Site

Lincoln, Nebraska 68510
United States

Research Site

Cleveland, Ohio 44106
United States

Research Site

Portland, Oregon 97213
United States

Research Site

Knoxville, Tennessee 37920
United States

Research Site

Leuven 3000
Belgium

Research Site

Calgary, Alberta T2N 4Z6
Canada

Research Site

Edmonton, Alberta T6G 2B7
Canada

Research Site

Toronto, Ontario M4N 3M5
Canada

Research Site

Montreal, Quebec H3A2B4
Canada

Research Site

Clermont-Ferrand cedex, Puy De Dome 63003
France

Research Site

Ulm, Baden Wuerttemberg 89081
Germany

Research Site

Torino 10126
Italy

Research Site

Bunkyo-ku
Japan

Research Site

Kagoshima-shi
Japan

Research Site

Shinjuku-ku
Japan

Research Site

Suita-shi
Japan

Research Site

Christchurch 8011
New Zealand

Research Site

Sheffield, South Yorkshire S102HQ
United Kingdom